Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Pelthos Therapeutics Inc.AMEX: PTHS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $10.24M (cash outflow) rose 420.3% year over year, behind the +600.9% change in trailing-twelve-month net income. Sequentially, it fell 52.7% from the prior quarter. Over 3 fiscal years it compounded at +160.2% a year.
Context
- Net income amounted to 257.9% of revenue in FY2025.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$29.79M (-31.2%) for the fiscal year ending Dec 2026, a slowdown from the +444.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.24M-52.7% QoQ
- Last fiscal yearDec 2025
- -$43.32M+444.5% YoY
- LTMMar 2026
- -$51.59M+600.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +420.3% | +189.3% | -231.1 pp |
| 1 year | +444.5% | -31.2% | -475.8 pp |
| 3-year CAGR | +160.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (43.32M) USD
- Year-over-year change
- -444.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (43.32M) | -444.5% |
| FY2024 | 2024-12-31 | (7.96M) | -7.8% |
| FY2023 | 2023-12-31 | (7.38M) | -200.2% |
| FY2022 | 2022-12-31 | (2.46M) | — |
Net Income vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's LTM Mar 2026 net income of $51.59M is the 2nd largest of the 4 companies compared; the peer median is $7.22M.
- Its year-over-year change of +600.9% is the 2nd highest of 4, against a peer median of +117.3%.
- Net income amounts to 186.2% of revenue for PTHS.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $1.24B | +8329.2% | — | — | |
| LTM Mar 2026 | $51.59M | +600.9% | +160.2% | 186.2% | |
| LTM Mar 2026 | $27.71M | +69.2% | +8.3% | — | |
| LTM Mar 2026 | $7.22M | +117.3% | -1.6% | — | |
| Peer median (excluding PTHS) | $7.22M | +117.3% | +3.3% | — | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (2.46M) | (7.38M) | (7.96M) | (43.32M) |
| Depreciation & Amortization | 0 | 0 | 0 | 2.36M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 110.15K | 1.73M | 1.8M | 0 |
| Change in Working Capital | 640.86K | 2.05M | 34.63K | (6.07M) |
| Accounts Receivables | 0 | 0 | (45.79K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 1.78M |
| Accounts Payables | 413.6K | 1.63M | 1.18M | 1.36M |
| Other Working Capital | 227.26K | 424.07K | (1.1M) | (395K) |
| Other Non-Cash Items | 140.43K | 2.62M | 328.93K | 24.44M |
| Operating Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.59M) |
| Capital Expenditures | 0 | 0 | 0 | (99K) |
| Acquisitions (Net) | 0 | 0 | 0 | (5.14M) |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (5.24M) |
| Debt Repayment | 400K | 766.94K | 321.43K | 17.75M |
| Common Stock Issued | 0 | 255.41K | 6.05M | 27.59M |
| Common Stock Repurchased | 0 | 0 | (166.51K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.22M | 0 | 0 | 0 |
| Financing Cash Flow | 1.62M | 1.02M | 6.21M | 45.34M |
| Effect of Forex Changes | 0 | 0 | 0 | (443) |
| Net Change in Cash | 55.07K | 41.32K | 417.05K | 17.51M |
| Free Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.69M) |
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.